cadenas

ITCC-037 DABRAFENIB

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

ITCC-037 DABRAFENIB

Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors

Promotor Name : GlaxoSmithKline

Investigator Name : B. GEOERGER

Trial registered on clinicaltrial.gov: NCT01677741